Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer.
Mariane Le FurAlana RossPamela PantazopoulosNicholas RotileIris ZhouPeter CaravanZdravka MedarovaByunghee YooPublished in: Cancer nanotechnology (2021)
Our results demonstrate that PET-MRI following a microdose injection of the agent will accurately reflect the innate biodistribution of the therapeutic. The tools developed in the present study lay the groundwork for the clinical testing of MN-anti-miR10b and other similar therapeutics in patients with cancer.
Keyphrases
- metastatic breast cancer
- contrast enhanced
- pet imaging
- computed tomography
- magnetic resonance imaging
- positron emission tomography
- immune response
- pet ct
- small cell lung cancer
- squamous cell carcinoma
- diffusion weighted imaging
- papillary thyroid
- room temperature
- metal organic framework
- squamous cell
- magnetic resonance
- lymph node metastasis